Visit COVID-19 resources

[Skip to Content]

Clinical outcomes between optical path difference custom aspheric treatment and optimized prolate ablation photorefractive keratectomy in myopia exceeding 8 diopters – (Eye 29, 356 (March 2015))

Mar 12
2015

Clinical outcomes between optical path difference custom aspheric treatment and optimized prolate ablation photorefractive keratectomy in myopia exceeding 8 diopters Eye 29, 356 (March 2015). doi:10.1038/eye.2014.272 Authors: B J Choi, Y M Park & J S Lee

  • 12 March 2015

Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction – (Eye 29, 363 (March 2015))

Mar 12
2015

Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction Eye 29, 363 (March 2015). doi:10.1038/eye.2014.294 Authors: R R Khandelwal, D Raje, A Rathi, A Agashe, M Majumdar & R Khandelwal

  • 12 March 2015

Choroid thickness and ocular pulse amplitude in migraine during attack – (Eye 29, 371 (March 2015))

Mar 12
2015

Choroid thickness and ocular pulse amplitude in migraine during attack Eye 29, 371 (March 2015). doi:10.1038/eye.2014.299 Authors: M S Dervisogullari, Y Totan & O S Gençler

  • 12 March 2015

MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy – (Eye 29, 376 (March 2015))

Mar 12
2015

MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy Eye 29, 376 (March 2015). doi:10.1038/eye.2014.298 Authors: M Citirik, E Beyazyildiz, M Simsek, O Beyazyildiz & I C Haznedaroglu

  • 12 March 2015

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA – (Eye 29, 380 (March 2015))

Mar 12
2015

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA Eye 29, 380 (March 2015). doi:10.1038/eye.2014.308 Authors: A J Lotery & S Regnier

  • 12 March 2015